Brainstorm Cell Therapeutics, Inc.
BCLI
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.36M
Close$
$-0.02
101.7% downside
Current Fair Value
101.7% downsideOvervalued by 101.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.36 Million |
|---|---|
| Enterprise Value | $13.71 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.11 |
| Beta | 0.24 |
| Outstanding Shares | 11,034,775 |
Return
| Return on Equity | -120.42% |
|---|---|
| Return on Assets | 3039.41% |
| Return on Invested Capital | -47.53% |
Valuation & Multiples
| P/E Ratio | -1.18 |
|---|---|
| PEG | -3.6 |
| Price to Sales | - |
| Price to Book Ratio | -0.58 |
| Enterprise Value to Revenue | 15.56 |
| Enterprise Value to EBIT | 2.42 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | -0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 3.69% |
|---|---|
| Total Invested | $1,727▼ 99.35% |
| Investors Holding | 5▼ 28.00% |
ESG Score
No data
About Brainstorm Cell Therapeutics, Inc.
CEO: Chaim Lebovits